Cystic Fibrosis (cf) Therapeutics Market By Drug Class, And Route Of Administration- Global Industry Analysis And Forecast To 2023

2018-05-30 / 3800.00 / Pharma & Healthcare / 111 Pages

Description

Industry Outlook and Trend Analysis

The Cystic Fibrosis (CF) Therapeutics Market was worth USD 2.15 billion in 2014 and is expected to reach approximately USD 22.46 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 29.79% during the forecast period. Expanding commonness of Cystic Fibrosis (CF) combined with rising rate of treatment is one of the key variables expected to push the interest for these therapeutics over the figure time frame. In addition, increment in R&D subsidizing by both private and open associations, rising number of activities attempted by philanthropic associations, and existence of ideal reimbursement policies are a portion of the essential elements anticipated that would drive the market in the coming few years. Moreover, expanding number of clinical trials to extend its objective patient base with the current medication portfolio is likewise among a portion of the drivers of this market.

Drug Class Outlook and Trend Analysis

On the basis of drug class, the market is sectioned into pancreatic enzyme supplements, bronchodilators, mucolytics, and CFTR modulators. The main factor in the treatment of CF is keeping up the function of the lung while controlling respiratory infection and clearing airways routes of mucus, dealing with the wholesome treatment, and controlling the complications. In 2016, CFTR modulators represented the biggest revenue with a share of roughly 47.3% inferable from the launch of new drug Orkambi. This drug is in charge of adjusting the capacity of defective protein caused by the CF gene.

Route of Administration Outlook and Trend Analysis

On the basis of route of administration, the market is sectioned into inhaled route and oral drugs. Oral route represented the biggest share of almost 63.7% out of 2016 inferable from the favourable circumstances related with its organization, for example, accommodation and simplicity of usage without the assistance of a medicinal services proficient.

Regional Outlook and Trend Analysis

Geographically, the market is portioned into Europe, North America, Asia Pacific, Latin America, and Middle East and Africa. North America represented the biggest income of USD 2,396.4 million in 2016. CF is most pervasive in North America as a large portion of the general population influenced with CF is of Caucasian plunge. Nonetheless, Asia Pacific is foreseen to be the quickest developing fragment.

Competitive Insights

The leading players in the market are Teva Pharmaceutical Industries, Merck & Co, AbbVie Inc, Alcresta Therapeutics Inc, Vertex Pharmaceuticals, ALAXIA, Gilead Sciences, Allergan, Roche Holding AG, AstraZeneca and Novartis. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

The Cystic Fibrosis (CF) Therapeutics Market is segmented as follows-

By Drug Class:


Pancreatic enzyme supplements
Bronchodilators
CFTR modulators
Mucolytics


By Route of Administration:


Inhaled drugs
Oral drugs


By Region


North America



U.S
Canada
Mexico



Europe



Germany
France
UK
Italy
Spain
Rest of Europe



Asia-Pacific



Japan
China
Australia
India
South Korea
Rest of Asia Pacific



Rest of the World



Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others


Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2015 to 2023`
What will be the industry market growth from 2015 to 2023`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Expanding commonness of Cystic Fibrosis
3.2.2. Restraints
3.2.2.1. High Pricing
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Cystic Fibrosis Therapeutics Market, By Drug Class
4.1. Introduction
4.2. Global Cystic Fibrosis Therapeutics Sales, Revenue and Market Share By Drug Class (2014-2017)
4.2.1. Global Cystic Fibrosis Therapeutics Sales and Sales Share By Drug Class (2014-2017)
4.2.2. Global Cystic Fibrosis Therapeutics Revenue and Revenue Share By Drug Class (2014-2017)
4.3. Cystic Fibrosis Therapeutics Market Assessment and Forecast, By Drug Class, 2014-2023
4.4. Pancreatic enzyme supplements
4.4.1. Market Assessment and Forecast, By Region, 2014-2023($Million)
4.5. Bronchodilators
4.5.1. Market Assessment and Forecast, By Region, 2014-2023($Million)
4.6. CFTR modulators
4.6.1. Market Assessment and Forecast, By Region, 2014-2023($Million)
4.7. Mucolytics
4.7.1. Market Assessment and Forecast, By Region, 2014-2023($Million)
5. Cystic Fibrosis Therapeutics Market, By Route of Administration
5.1. Introduction
5.2. Global Cystic Fibrosis Therapeutics Sales, Revenue and Market Share By Route of Administration (2014-2017)
5.2.1. Global Cystic Fibrosis Therapeutics Sales and Sales Share By Route of Administration (2014-2017)
5.2.2. Global Cystic Fibrosis Therapeutics Revenue and Revenue Share By Route of Administration (2014-2017)
5.3. The Cystic Fibrosis Therapeutics Market Assessment and Forecast, By Route of Administration, 2014-2023
5.4. Inhaled drugs
5.4.1. Market Assessment and Forecast, By Region, 2014-2023($Million)
5.5. Oral drugs
5.5.1. Market Assessment and Forecast, By Region, 2014-2023($Million)
6. Cystic Fibrosis Therapeutics Market, By Region
6.1. Introduction
6.2. Cystic Fibrosis Therapeutics Market Assessment and Forecast, By Region, 2014-2023 ($Million)
6.3. Global Cystic Fibrosis Therapeutics Sales, Revenue and Market Share by Regions
6.3.1. Global Cystic Fibrosis Therapeutics Sales by Regions (2014-2017)
6.3.2. Global Cystic Fibrosis Therapeutics Revenue by Regions (2014-2017)
6.4. North America
6.4.1. North America Cystic Fibrosis Therapeutics Sales and Growth Rate (2014-2017)
6.4.2. Market Assessment and Forecast, By Country, 2014-2023($Million)
6.4.3. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.4.4. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.4.5. U.S.
6.4.5.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.4.5.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.4.6. Canada
6.4.6.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.4.6.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.4.7. Mexico
6.4.7.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.4.7.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5. Europe
6.5.1. Europe Cystic Fibrosis Therapeutics Sales and Growth Rate (2014-2017)
6.5.2. Market Assessment and Forecast, By Country, 2014-2023($Million)
6.5.3. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.4. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5.5. Germany
6.5.5.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.5.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5.6. France
6.5.6.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.6.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5.7. UK
6.5.7.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.7.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5.8. Italy
6.5.8.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.8.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5.9. Spain
6.5.9.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.9.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.5.10. Rest of Europe
6.5.10.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.5.10.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6. Asia-Pacific
6.6.1. Asia-Pacific Cystic Fibrosis Therapeutics Sales and Growth Rate (2014-2017)
6.6.2. Market Assessment and Forecast, By Country, 2014-2023($Million)
6.6.3. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.4. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6.5. Japan
6.6.5.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.5.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6.6. China
6.6.6.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.6.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6.7. Australia
6.6.7.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.7.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6.8. India
6.6.8.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.8.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6.9. South Korea
6.6.9.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.9.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.6.10. Rest of Asia-Pacific
6.6.10.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.6.10.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7. Rest of the World
6.7.1. Rest of the World Cystic Fibrosis Therapeutics Sales and Growth Rate (2014-2017)
6.7.2. Market Assessment and Forecast, By Country, 2014-2023($Million)
6.7.3. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.4. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7.5. Brazil
6.7.5.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.5.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7.6. Turkey
6.7.6.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.6.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7.7. Saudi Arabia
6.7.7.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.7.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7.8. South Africa
6.7.8.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.8.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7.9. United Arab Emirates
6.7.9.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.9.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
6.7.10. Others
6.7.10.1. Market Assessment and Forecast, By Drug Class, 2014-2023($Million)
6.7.10.2. Market Assessment and Forecast, By Route of Administration, 2014-2023($Million)
7. Company Profiles
7.1. Teva Pharmaceutical Industries
7.1.1. Business Overview
7.1.2. Product Portfolio
7.1.3. Strategic Developments
7.1.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.2. Merck & Co
7.2.1. Business Overview
7.2.2. Product Portfolio
7.2.3. Strategic Developments
7.2.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.3. AbbVie Inc
7.3.1. Business Overview
7.3.2. Product Portfolio
7.3.3. Strategic Developments
7.3.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.4. Alcresta Therapeutics Inc
7.4.1. Business Overview
7.4.2. Product Portfolio
7.4.3. Strategic Developments
7.4.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.5. Vertex Pharmaceuticals
7.5.1. Business Overview
7.5.2. Product Portfolio
7.5.3. Strategic Developments
7.5.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.6. Allergan
7.6.1. Business Overview
7.6.2. Product Portfolio
7.6.3. Strategic Developments
7.6.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.7. Roche Holding AG
7.7.1. Business Overview
7.7.2. Product Portfolio
7.7.3. Strategic Developments
7.7.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.8. AstraZeneca
7.8.1. Business Overview
7.8.2. Product Portfolio
7.8.3. Strategic Developments
7.8.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
7.9. Novartis
7.9.1. Business Overview
7.9.2. Product Portfolio
7.9.3. Strategic Developments
7.9.4. Cystic Fibrosis Therapeutics Sales, Revenue and Market Share
8. Global Cystic Fibrosis Therapeutics Market Competition, by Manufacturer
8.1. Global Cystic Fibrosis Therapeutics Sales and Market Share by Manufacturer (2016-2017)
8.2. Global Cystic Fibrosis Therapeutics Revenue and Market Share by Manufacturer (2016-2017)
8.3. Top 5 Cystic Fibrosis Therapeutics Manufacturer Market Share
8.4. Market Competition Trend
List of Tables and Figures
*You can glance through the list of Tables and Figures when you view the sample copy of Cystic Fibrosis Therapeutics Market.


Table of Figures

*You can glance through the list of Tables and Figures when you view the sample copy of Biomass Energy Market.

Request Sample

* mark fields are compulsory